ScholarIQanswers from OpenAlex & ORCID
Hanno Riess
ResearcherPublications, citations & collaboration network
Hanno Riess is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hanno Riess have?
ScholarIQindexed works
Hanno Riess has 519 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hanno Riess have?
ScholarIQcitation count
Hanno Riess has 21,614 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hanno Riess?
ScholarIQh-index
Hanno Riess has an h-index of 62 in OpenAlex.
What is the i10-index of Hanno Riess?
ScholarIQi10-index
Hanno Riess has an i10-index of 228 in OpenAlex.
What is the OpenAlex record for Hanno Riess?
ScholarIQopenalex
The OpenAlex for Hanno Riess is on the source record.
What are the most-cited papers on Hanno Riess?
ScholarIQmost cited works
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Alok A. Khorana, Gerald A. Soff, Ajay K. Kakkar, Saroj Vadhan‐Raj, Hanno Riess, Ted Wun, Michael B. Streiff, David García, Howard A. Liebman, Chandra P. Belani, Eileen M. O’Reilly, Jai N. Patel, Habte Yimer, Peter Wildgoose, Paul Burton, Ujjwala Vijapurkar, Simrati Kaul, John W. Eikelboom, Robert D. McBane, Kenneth A. Bauer, Nicole M. Kuderer, Gary H. Lyman
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Dominique Farge, Corinne Frère, Jean M. Connors, Alok A. Khorana, Ajay K. Kakkar, Cihan Ay, Andres Muñoz, Benjamin Brenner, Pedro Henrique Prata, Dialina Brilhante, Darko Antić, Patricia Casais, Cecilia Guillermo, Takayuki Ikezoe, Syed A. Abutalib, Luis Antonio Meillón‐García, Henri Bounameaux, Ingrid Pabinger, James D. Douketis, Walter Ageno, Fernando Ajauro, Thierry Alcindor, Pantep Angchaisuksiri, Juan I. Arcelus, Raquel Barba, Ali Bazarbachii, Audrey Bellesoeur, Okba Bensaoula, Ilham Benzidia, Darius Bita, Viktoria Bitsadze, Dorit Blickstein, Mark Blostein, Isabel Bogalho, A.A.G.S. Brandāo, Rodrigo T. Calado, Alain Carpentier, José Ceresetto, Rufaro S Chitsike, J. Connault, Catarina Jacinto Correia, Benjamin Crichi, Erich Vinícius De Paula, Ahmet Muzaffer Demir, Laure Deville, Ludovic Doucet, Vera Dounaevskaia, C. Durant, Ellis Martin, Joseph Emmerich, Anna Falanga, Carme Font, Enrique Gallardo, Thomas Gary, Filipe Gonçalves, Jean‐Christophe Gris, Hiromi Hayashi, A. Hij, Luis Jara‐Palomares, David Jiménez, J. Kh. Khizroeva, Michel N'Guessan, Florian Länger, C. Le Hello, Christine Le Maignan, Ramón Lecumberri, Lai Heng Lee, Zachary Liederman, Luisa Lopes dos Santos, Duarte Machado, А. D. Makatsariya, Alberto Maneyro, Zora Marjanovic, Serban Milhaileanu, Manuel Monréal, Sara Moráis, António Moreira, Mikio Mukai, Arlette Ndour, Luciana Correa Oliveira de Oliveira, Remedios Otero-Candelara, Maria Carolina Tostes Pintão, Florian Posch, Pascal Prilollet, Hanadi Rafii, Daniel Dias Ribeiro, Hanno Riess, Marc Righini, Helia Robert‐Ebadi, Cynthia Rothschild, André Roussin, José Antonio Rueda Camino, Pedro Ruiz‐Artacho, Gleb Saharov, Joana Santos, M. Sebuhyan, Ali Shamseddine, Galia Spectre, Alì Taher, Javier Trujillo‐Santos
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, R. Neuhaus, H. Lehmkuhl, Heinz A. Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphaël, Hanno Riess, Sylvain Choquet